Cyclosporine-Induced Hypertension

Mechanism and Risk Factors

Cyclosporine causes hypertension in approximately 20% of patients, with the hypertension generally improving when the medication is discontinued, according to the British Journal of Dermatology 1, 2, 3
The pathogenesis is thought to be primarily due to a vasoconstrictive effect on vascular smooth muscle, particularly in the kidney, as reported by the British Journal of Dermatology 1, 2
Research in transplant recipients has confirmed cyclosporine-induced nitric oxide (NO) system upregulation, with possible cyclosporine-induced production of superoxide leading to NO destruction, inducing vasoconstriction and hypertension, as found by the British Journal of Dermatology 2, 3
Hypertension can develop at any time during treatment with cyclosporine, and it is more commonly seen in patients over 45 years of age, according to the British Journal of Dermatology 1, 2, 3
Patients with pre-existing or borderline hypertension are at greater risk, as reported by the British Journal of Dermatology 2, 3

The development of hypertension does not automatically necessitate cessation of cyclosporine therapy, according to the British Journal of Dermatology 2, 3
Management options include reducing the cyclosporine dosage if hypertension occurs, treating the hypertension with appropriate medications, and discontinuing cyclosporine if a satisfactory blood pressure cannot be maintained, as recommended by the British Journal of Dermatology 2, 3 and the Journal of the American Academy of Dermatology 4
Calcium channel blockers are the preferred antihypertensive agents due to their ability to relax vascular smooth muscles, as reported by the Journal of the American Academy of Dermatology 4, 5
Recommended calcium channel blockers include nifedipine, isradipine, felodipine, or amlodipine, which do not interact with cyclosporine metabolism and are also nephroprotective, according to the British Journal of Dermatology 2, 3 and the Journal of the American Academy of Dermatology 4

Regular blood pressure monitoring is essential, and early morning resting blood pressure is a more sensitive indicator of early nephrotoxicity than elevated creatinine, as reported by the Journal of the American Academy of Dermatology 4
If hypertension is observed on 2 separate occasions, the dose of cyclosporine should be decreased, according to the Journal of the American Academy of Dermatology 4
Hypertension is a contraindication to initiating cyclosporine therapy, as reported by the Journal of the American Academy of Dermatology 4, 5